Paragon 28, Inc. (FNA)

Paragon 28, Inc. (FNA) Healthcare & Pipeline Overview

Paragon 28, Inc. is a medical device company focused on developing and commercializing a comprehensive portfolio of foot and ankle surgical solutions. With specialized plating systems, precision guide technology, and orthobiologics, the company addresses complex orthopedic conditions, serving hospitals and ambulatory surgery centers in the United States and internationally.

What Is the Investment Thesis for FNA?

Paragon 28, Inc. operates within the specialized and growing foot and ankle orthopedic market, demonstrating a robust product development strategy with a comprehensive portfolio of surgical systems, implants, and orthobiologics. The company's high gross margin of 74.7% indicates strong product pricing power and efficient manufacturing, which are critical for long-term profitability in the medical device sector. Key growth catalysts include the continued adoption of its innovative precision guide technology, expansion of its total ankle replacement systems like APEX 3D, and the increasing demand for specialized orthobiologics. The company's focus on a niche, yet complex, anatomical area allows for deep market penetration and specialized expertise. However, the current profit margin of -21.3% indicates ongoing investments in growth and operational scale, requiring careful monitoring of its path to profitability. With a market capitalization of $1.10B and a Beta of 1.47, the stock exhibits higher volatility relative to the broader market, suggesting sensitivity to market sentiment and operational performance. Future value drivers will likely stem from successful new product introductions, market share gains in both domestic and international markets, and eventual leverage of its high gross margin into positive net income.

Based on FMP financials and quantitative analysis

FNA Key Highlights

• Gross margin of 74.7% reflects strong product profitability and efficient cost management within its specialized medical device offerings.
• Negative profit margin of -21.3% indicates significant ongoing investments in research, development, and market expansion efforts.
• Market capitalization of $1.10B positions Paragon 28, Inc. as a mid-cap player in the medical devices industry.
• A Beta of 1.47 suggests the company's stock experiences higher volatility compared to the overall market, indicating greater sensitivity to market fluctuations.
• The company employs 525 individuals, supporting its specialized product development, distribution, and sales operations across its global footprint.

Who Are FNA's Competitors?

FNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FNA's Key Strengths?

• Specialized and comprehensive product portfolio for foot and ankle surgery.
• High gross margin of 74.7% indicates strong product economics.
• Innovative precision guide technology and advanced implant systems.
• Established distribution network to hospitals and ambulatory surgery centers.
• Focus on a growing niche within the orthopedic market.

What Are FNA's Weaknesses?

• Negative profit margin of -21.3% indicates current unprofitability.
• Relatively smaller market capitalization compared to diversified orthopedic giants.
• High Beta of 1.47 suggests increased stock price volatility.
• Reliance on a specific anatomical focus, potentially limiting broader market diversification.

What Could Drive FNA Stock Higher?

• Potential introduction of new advanced plating systems or orthobiologics, expanding the company's comprehensive product portfolio.
• Strategic expansion into new international markets, broadening the company's global distribution and revenue base.
• Continued adoption and increased utilization of the APEX 3D total ankle replacement system and precision guide technology by orthopedic surgeons.
• Growth in demand for specialized foot and ankle surgical procedures driven by demographic trends and increased prevalence of related conditions.

What Are the Key Risks for FNA?

• Negative return on equity (-35.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $14.7M recently.
• Sustained negative profit margin of -21.3% indicates continued operational losses, which could impact long-term financial stability if not addressed.
• Intense competition within the medical device industry, particularly from larger, diversified orthopedic companies, could pressure market share and pricing.
• Stringent and evolving regulatory requirements for medical devices, which could delay product approvals or increase compliance costs.
• Product liability claims or recalls, which could lead to significant financial costs and reputational damage.
• High stock volatility, as indicated by a Beta of 1.47, suggests the company's share price is more sensitive to market fluctuations and investor sentiment.

What Are the Growth Opportunities for FNA?

• **Expansion of Total Ankle Arthroplasty Market:** The market for total ankle replacement systems, such as Paragon 28's APEX 3D, is experiencing significant growth as an alternative to traditional ankle fusion, driven by improved implant designs and surgical techniques. As patient awareness increases and clinical outcomes improve, the adoption of total ankle arthroplasty is projected to expand, offering Paragon 28 a substantial opportunity to capture market share. The global ankle replacement market is estimated to be growing, with projections indicating continued expansion over the next decade, providing a long-term growth runway for the company's advanced solutions in this segment.
• **International Market Penetration:** Paragon 28 currently operates in the United States and internationally, but there remains significant untapped potential in expanding its global footprint. Many international markets, particularly in emerging economies, are experiencing increased healthcare spending and a growing demand for advanced orthopedic solutions. By strategically expanding its sales channels and regulatory approvals in key international regions, Paragon 28 can diversify its revenue streams and access new patient populations. This geographic expansion could involve establishing new distribution partnerships or direct sales forces, offering substantial long-term growth prospects.
• **Advancements in Orthobiologics:** The orthobiologics market, which includes bone wedges, grafts, and synthetic materials like those offered by Paragon 28, is a high-growth area within orthopedics. These products enhance healing and improve surgical outcomes, making them increasingly integral to complex foot and ankle procedures. Continued innovation and expansion of Paragon 28's orthobiologics portfolio, including new formulations or applications, can drive significant revenue growth. The global orthobiologics market is projected to reach substantial valuations, indicating a robust and expanding demand for these supportive surgical materials over the coming years.
• **Increased Adoption of Precision Guide Technology:** Paragon 28's precision guide technology, designed for procedures like bunion correction and Charcot foot reconstruction, offers enhanced accuracy and reproducibility for surgeons. As surgical techniques evolve and the demand for minimally invasive and highly precise interventions grows, the adoption of such advanced guidance systems is likely to accelerate. This technology provides a competitive advantage by potentially reducing operative time and improving patient outcomes, thereby increasing its appeal to hospitals and ambulatory surgery centers. Further development and integration of this technology into more procedures represent a significant growth avenue for the company over the medium term.
• **Addressing Degenerative and Deformity Conditions:** The prevalence of degenerative conditions like osteoarthritis and complex deformities such as severe hallux valgus (bunions) and Charcot foot continues to rise globally. Paragon 28's specialized systems, including its Phantom intramedullary nail systems for bunion correction and medial column beaming for Charcot foot, directly address these widespread and often debilitating conditions. As healthcare systems focus on improving patient mobility and reducing long-term disability, the demand for effective surgical solutions for these conditions will persist and grow. Ongoing product enhancements and educational initiatives for surgeons can further solidify Paragon 28's position in these critical treatment areas.

What Opportunities Does FNA Have?

• Expansion into new international markets to diversify revenue streams.
• Continued innovation and launch of new products in orthobiologics and total ankle arthroplasty.
• Increasing demand for specialized foot and ankle surgical solutions due to demographic trends.
• Leveraging precision guide technology for broader procedural applications and improved outcomes.
• Potential for market share gains from competitors through superior product offerings and surgeon training.

What Threats Does FNA Face?

• Intense competition from larger, more established medical device companies.
• Stringent regulatory approval processes for new products and market access.
• Potential for product liability claims inherent in medical device manufacturing.
• Economic downturns or changes in healthcare reimbursement policies affecting elective surgeries.
• Technological obsolescence requiring continuous R&D investment.

What Are FNA's Competitive Advantages?

• Highly specialized and comprehensive product portfolio exclusively for foot and ankle surgery, fostering deep expertise.
• Proprietary precision guide technology enhancing surgical accuracy and reproducibility.
• Extensive range of plating systems, total ankle replacements, and orthobiologics addressing diverse pathologies.
• Established distribution network serving hospitals and ambulatory surgery centers.
• Focus on innovation within a niche market, potentially leading to strong surgeon loyalty.

What Does FNA Do?

Paragon 28, Inc., founded in 2010 and headquartered in Englewood, Colorado, is a dedicated designer, developer, distributor, and seller of specialized foot and ankle surgical systems. The company has evolved to offer a comprehensive suite of products aimed at addressing a wide range of orthopedic conditions affecting the lower extremities. Its extensive product portfolio includes advanced plating systems, such as the Gorilla and Silverback lines, which feature specialized plates like Lisfranc, Lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems, along with plate-specific screws and fracture plates. Paragon 28 also provides innovative precision guide technology, facilitating accurate procedures for bunion deformities, first tarsometatarsal arthrodesis, metatarsal osteotomy, Charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. Beyond fixation, the company offers Monster, Mini Monster, and Joust beaming screw systems for bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, and fracture repair. A significant offering is the APEX 3D total ankle replacement system and total talus spacers, which provide solutions for severe ankle pathologies. Furthermore, Paragon 28's product line extends to bunion correction systems, including Phantom intramedullary nail systems for severe hallux valgus, and a diverse range of orthobiologics such as bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and the PRESERVE bone graft system. Complementing these are soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and specialized curved instruments. The company distributes its products to hospitals and ambulatory surgery centers through a robust network of sales representatives and stocking distributors, establishing a significant presence in the specialized medical device market both domestically and internationally.

What Products and Services Does FNA Offer?

• Designs, develops, distributes, and sells foot and ankle surgical systems.
• Offers plating systems, including Gorilla and Silverback lines, for various foot and ankle fusions and fracture repairs.
• Provides precision guide technology for accurate surgical procedures like bunion correction and Charcot foot reconstruction.
• Manufactures beaming screw systems (Monster, Mini Monster, Joust) for bone reconstruction and fixation.
• Develops and sells APEX 3D total ankle replacement systems and total talus spacers.
• Offers bunion/hallux valgus correction systems, including Phantom intramedullary nail systems.
• Provides a range of orthobiologics, such as bone wedges, grafts, demineralized bone matrices, and synthetic materials.
• Supplies soft tissue fixation systems, titanium implants, nitinol staples, and specialized surgical instruments.

How Does FNA Make Money?

• Generates revenue by selling specialized foot and ankle surgical systems, implants, and orthobiologics.
• Distributes products to hospitals and ambulatory surgery centers.
• Utilizes a network of sales representatives and stocking distributors for market reach and product delivery.
• Focuses on innovation and product development to address evolving surgical needs and maintain a competitive edge.
• Emphasizes comprehensive solutions for a wide range of foot and ankle pathologies.

What Industry Does FNA Operate In?

Paragon 28, Inc. operates within the dynamic and growing medical devices industry, specifically targeting the foot and ankle orthopedic segment. This niche market is characterized by increasing demand driven by an aging global population, rising incidence of diabetes-related foot complications, sports injuries, and a general increase in patient expectations for mobility and quality of life. The competitive landscape includes both large diversified orthopedic companies and smaller, specialized players. Paragon 28 differentiates itself through its comprehensive and specialized product portfolio, which covers a wide array of foot and ankle pathologies, from bunion correction to complex ankle replacements and reconstruction. The industry is highly regulated, requiring significant investment in R&D and clinical trials to bring new products to market. Market trends indicate a shift towards less invasive procedures, personalized medicine, and advanced biomaterials, areas where Paragon 28's precision guide technology and orthobiologics offerings position it for potential growth. The company's focus on a specific anatomical area allows it to build deep expertise and strong relationships with specialized surgeons.

Who Are FNA's Key Customers?

• Hospitals requiring specialized orthopedic surgical equipment.
• Ambulatory surgery centers performing foot and ankle procedures.
• Orthopedic surgeons specializing in foot and ankle surgery.
• Healthcare providers seeking advanced solutions for complex lower extremity conditions.

How Paragon 28, Inc. Is Valued

Paragon 28, Inc. carries a market capitalization of $1.10B, placing it in the small-cap category. Relative to its peer group, FNA's quantitative score of 51/100 is below the peer average of 69/100.

Company Profile

Paragon 28, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Englewood, US. The company is led by CEO Albert DaCosta. FNA has traded publicly since 2021.

ROE -35%Key Financial Metrics

Return on equity for Paragon 28, Inc. stands at -35.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.51 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Paragon 28, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.16 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Paragon 28, Inc. revenue of about $333.0M for fiscal 2026, with EPS near $-0.35. The estimate reflects 4 contributing analysts.

Net sellingInsider Activity

The most recent 12 insider filings for Paragon 28, Inc. break down as 12 sales and 0 purchases. On net that is roughly 1.4M shares disposed (about $14.7M), a signal worth weighing alongside the fundamentals.

FNA Financials

FNA Latest News

No recent news available for FNA.

FNA Analyst Consensus

FNA MoonshotScore

Paragon 28, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources